A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

NCT05559008 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Azacitidine Injection
DRUG: Dasatinib
DRUG: Linperlisib
DRUG: Tucidinostat
DRUG: SHR2554
DRUG: Camrelizumab
DRUG: Apatinib

Sponsor

Ruijin Hospital